Dechra Veterinary Products has launched Sporimune (ciclosporin), licensed for the treatment of chronic manifestations of atopic dermatitis in dogs.
Roger Brown, Senior Brand Manager at Dechra Veterinary Products, said: "Around 20% of all small animal consultations involve skin conditions and canine atopic dermatitis can be challenging to diagnose and manage effectively.
"Although incurable, atopic dermatitis can be managed using a multimodal approach which is likely to include treatments to decrease pruritus as well as allergen identification, avoidance where possible and improving skin and coat hygiene."
Sporimune is a 50 mg/ml oral solution administered by syringe, which is graduated to show both bodyweight and ml. Dechra says it is being introduced to veterinary professionals within the company's Partners in Practice programme which aims to support vets and vet nurses as they diagnose, control and maintain complex dermatological conditions.
Mr Brown added: "It is critical that owners are fully involved and educated about their pet's condition for dogs to be treated effectively. So we have also developed support materials around the use of Sporimune for practices, including client information leaflets and a video on how to use the dosing syringe."
Sporimune is now available from veterinary wholesalers. For further information visit www.dechra.co.uk/sporimune.
The company is now inviting practices to sign up for the free Beta trial and shape the development of the new platform and how video consultations can be integrated into traditional ways of working.
The platform, which can be branded with the practice logo, uses an app which clients download onto their mobile devices and use to book appointments. The system has its own appointment booking system, but also integrates with Vetstoria. When an appointment is booked via video, practitioners see it in their PMS. They then visit their online account, select the relevant appointment and click ‘start video call’. Payment can be collected from the owner prior to the consultation.
Susie Samuel, Managing Director of VetHelpDirect said: "While developing this product, we have been mindful that the use of telemedicine in our industry has been hugely controversial. We believe that inviting local vets to trial and refine this technology, using their team to work with their own clients removes many of the risks and dangers otherwise inherent in the proposition."
I agree wholeheartedly. The controversy over telemedicine has been about the idea of allowing the prescription of drugs to animals that have not been seen in person. Using a service like this (or the one launched by the Virtual Vet Group last year) to offer video consultations to patients that are already under your care strikes me as an altogether different kettle of fish. I think it will help improve engagement with existing clients, by reducing unnecessary trips to the practice for follow-up or post-operative consultations, saving time, money and the planet.
Susie added: "In our fast-moving world pet owners are increasingly reliant on technology and expect to be able to access services easily. The results of our recent VetHelpDirect research of 419 owners showed 38% of survey respondents said they would like to have the option of a video consultation if it was offered by their own vet. If we are to keep up with this demand, we need to embrace new ways of working."
VetHelpDirect says that whilst it believes that the growth in the use of this technology will change the way veterinary medicine is practiced, video consultations will always work alongside in-person consultations, as just one tool in an overall strategy of care, and certainly will not replace face to face diagnosis.
Let's hope so.
Susie added: "What is clear from our research is that whilst clients would like to be able to have video consultations with a vet their strong preference is for this to be with their own vet; whilst 38% of people would use video consultations with their own vet this falls to only 7% if it is provided by a vet not known to them.
"Of course, telemedicine is by no means the answer in every case, what the new service does offer is flexibility for practitioners and the ability to work in new ways that will benefit the animals and owners. For example, giving free telephone advice has become common place in many practices but is very hard to monetise. Video consultations provide a commercial solution to this problem.”
For more information, or to join the trial, contact Susie Samuel susie@vethelpdirect.com
Over 25% of the 1001 veterinary professionals who responded felt that the use of technology for triage and or consultations had either improved efficiency or the service offered to clients.
More than 10% said the pandemic had led to practices taking actions which streamlined client processes such as taking payments and booking appointments online or by phone.
The survey results are included in a presentation at the BSAVA Virtual Congress: "Lessons from Lockdown:Telemedicine is here to stay", which forms part of the current topics stream on Saturday 27th March. Brian Faulkner will take a look at maintaining relationships and changing dynamics with remote consults, communication challenges and opportunities. Matt Flann will follow with: "A practical perspective – how we have used it, what have we learned?"
BSAVA President Professor Ian Ramsey said: “The survey results have given us an important insight on how technology is being deployed to help the profession continue to help pets and their owners safely and to the best of their ability in these difficult circumstances.
"Vets have embraced innovations in practice such as telephone triage, remote consultations and digital communications. These have shown us that, as within the human healthcare sector, we can continue to deliver our vital services, possibly to an even more efficient and effective standard, despite the restrictions.
"Our Congress session on lockdown learnings promises to make for compelling listening with important ramifications for veterinary practice even after the pandemic has receded to a bitter memory. As we return to degrees of normality these innovations should not be discarded, but equally must not be allowed to generate the inequalities that go hand in hand with them if some practices and owners are inadvertently left behind.”
To register for BSAVA Congress, visit https://www.bsavaevents.com/bsavacongress2021/en/page/home
Reference
Pockit Central is a benchtop analyser which completes tests in 85 minutes.
The new PCR tests include: Lyme disease, Dirofilaria immitis, Neospora caninum, Pseudomonas aeruginosa, Mec A gene for MRSA, IBR and C. difficile. The system has tests tailored to small animal, equine and farm practice, with specialist assays also available for poultry and aquaculture.
The new additions extend the capabilities of the Pockit to more than 190 assays, testing up to 8 pathogens in one run. Horiba says the Pockit is so easy to set up that a laboratory can be up and running within 30 minutes with staff training provided.
Horiba has also published its recent veterinary CPD webinar in which the value of in-house PCR analysis for pathogen screening is discussed with the Head of ESCCAP (European Scientific Council for Companion Animal Parasites) UK & Ireland, in conjunction with the importance of screening imported dogs: The webinar is available to watch on-demand at: https://www.horiba.com/en_en/veterinary/support/webinars/
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
Petplan is giving away a VIP trip for two people to this year's 'Petplan Veterinary Awards' in Birmingham on 31st March.
The prize includes two admission tickets to the awards ceremony, as well as accommodation at a top hotel in Birmingham.
Veterinary staff can be in with a chance at winning this exclusive opportunity by nominating their practice or a member of staff for the following awards:
Alison Andrew, Petplan's Marketing Manager, said, "Veterinary professionals up and down the country show great commitment and dedication to our pets everyday and the awards are an opportunity to recognise all their hard work. By nominating a colleague you can not only show them your appreciation but you can also going into the draw to win a fantastic night out"
By making a nomination at www.petplan.co.uk/vetawards you'll automatically be entered into the draw to win the VIP tickets to the evening.
Nominations for the awards close on the 4th February and the winner of the VIP tickets will be announced in late February.
CVS says that in the USA, the veterinary profession is the fifth highest profession for non-fatal injuries, with equine veterinarians sustaining an average of eight serious injuries during their career.
‘The context, consequence and prevention of veterinary workplace injuries: a qualitative and quantitative study in the UK’ will be undertaken at the University of Liverpool in collaboration with CVS colleagues as part of its Clinical Research Awards.
The study will run for three years, supported by £74,400 of CVS funding.
The research will investigate what veterinary injuries are, what context they occur in and what their consequences are.
It will look to highlight areas of the profession where injury prevention training and strategies can be developed and adopted to improve the safety of working in veterinary practice.
For the first phase, University of Liverpool researchers have rolled out the largest ever survey to explore veterinary workplace injuries with over 5,000 CVS staff UK-wide.
The survey investigates how veterinary professionals define injuries, their specific causal mechanisms, and why individuals do or do not report injuries or seek medical treatment.
The survey will be followed by an independent audit of CVS’ accident reporting system.
The results of these two activities will lead to the development of a suite of industry leading ‘open access’ educational tools aimed at promoting injury awareness and prevention to help drive behaviour change and support injury avoidance.\
The research project is being led by Dr. John Tulloch, a Research Fellow and European Specialist in Veterinary Public Health, at the University of Liverpool.
Collaborators include CVS Head of Health and Safety Rebecca Jackson and Director of Learning, Education and Development Dr Martin Whiting.
John said: “Injuries that occur within veterinary practice can tragically at times be life-changing and are often avoidable.
"Currently we do not know some critical details that would help to improve safety within the veterinary workplace.
"If we can better understand these details, we will be able to develop and strengthen prevention measures through policy, education, and training.
"We anticipate that this project will result in safer workplaces within the wider veterinary community and, indirectly, in improved animal treatment through a fitter, healthier and safer profession.”
Research commissioned by Bayer Animal Health has revealed that dogs really do look like their owners.
The research, which is being used to promote Drontal Bone, the company's new bone-shaped wormer, was conducted amongst 3,000 British dog-lovers. It found that the overwhelming majority of owners share at least one common physical attribute with their pet, whilst one in ten owners could be described as the spitting image of their dog, sharing six or more physical attributes:
As part of the campaign, Bayer has launched the Give Your Dog a Bone competition, a nationwide search to find the UK's "Top Dog". The competition is split into four video and photographic categories, with one open exclusively to dogs that have formed a special bond with their owner. Top dogs can enter via the competition website - www.giveyourdogabone.co.uk - where owners can upload photos, videos, and explain in under 100 words why they think their pet should win a Drontal 'Bonies' award.
Give Your Dog a Bone Judge Emma Milne MRCVS, said: "When dogs seem to have the same characteristics as their owners, it could be because people subconsciously choose a pet that resembles themselves. It is often found that more energetic breeds, such as s Red Setter have an owner who is sporty and most happy when taking their pet on long country walks, while a glamorous owner who enjoys grooming themselves might choose a dog which also requires lots preening, such as a Maltese Terrier. The Give Your Dog a Bone awards give us the chance to recognise the unique traits and talents that make dogs such an important part of our lives. With four very different categories, this competition will be wide open to dogs of all shapes, sizes and personalities!"
Students of the five-year degree will spend two years at Aberystwyth University followed by three years’ study at the RVC’s Hawkshead Campus in Hertfordshire. The first cohort will start in 2021.
Professor Stuart Reid, Principal of the RVC said: "We are delighted to be partnering with our colleagues Aberystwyth in providing an offering that will benefit students at both institutions. The RVC’s commitment to the profession in all its manifestations and particularly the rural environment will be bolstered by this important collaboration."
Professor Elizabeth Treasure, Vice-Chancellor of Aberystwyth University said: "Today marks an important and exciting new chapter in the history of Aberystwyth University and Wales. Agriculture and its related industries play such an important part in the Welsh economy and it is incumbent on us as universities to provide the people and the skills that will contribute to ensuring they thrive for years to come. The new School of Veterinary Science adds a vitally important new piece to the jigsaw, one that will build resilience in the rural economy through education and research at a time of great potential change and challenges.
"Our students will enjoy the best of two worlds at universities that offer academic excellence and an enviable reputation for student experience, and I thank everyone who has contributed to finally realising the vision of a school of veterinary science for Wales."
Photo: Left to right, Professor Stuart Reid, Professor Christianne Glossop, Professor Elizabeth Treasure and Professor Tim Woods.
The new, four storey, architecturally-designed clinic is full of natural light and includes calming and spacious staff breakout areas.
By combining a beautiful work environment with seamless technology, the company believes it can transform working conditions and job satisfaction for vet teams.
On the tech side, the Creature Comforts has created a proprietary app which allows triage to be handled online and for staff to work flexibly.
The company says the app also reduces the administrative burden, a contributory factor for staff burnout.
Creature Comforts says most clients subscribe at a cost of £20 per pet per month, giving them unlimited consultations, instant bookings and live chat via the app (as well as annual vaccinations and discounted routine treatments).
This should mean animals are seen more frequently, and conditions can be identified and treated earlier.
Memberships will be capped to control vet team caseload and to ensure a good customer experience.
The company is also addressing Competition and Markets Authority concerns, with prices for routine treatments listed on its website, upfront estimates for procedures, and a business model hinged on unlimited access to expertise (i.e. consultations, instant in-app bookings and live chat) at no extra cost for subscribed members.
Creature Comforts says its vet team benefits from a share of their clinic’s profits, above industry-standard pay, compensated overtime, a well-balanced staffing ratio, manageable working hours and scheduled breaks.
Dr Russell Welsh, COO and co-founder of Creature Comforts, said: “It’s an incredible feeling to see a plan come together in a sector that’s so ripe for transformation.
"We want to bring the passion, joy and fun back to our profession, and this is an opportunity to do things differently and vastly better, with a fresh and carefully-considered business model founded on the principles of health and happiness.
"This is vet care as it should be."
https://www.creaturecomforts.co.uk
The RCVS is seeking feedback on a new draft Code of Professional Conduct.
The new Code, which would replace the existing RCVS Guide to Professional Conduct for Veterinary Surgeons, has been produced by a Working Party set up by the RCVS Advisory Committee to review the Guides for both veterinary surgeons and veterinary nurses.
According to the College, the purpose of the review, which last took place over a decade ago, is to ensure guidance to the profession and the public is clear. For example, using consistent language to distinguish between what must be done and what is advised.
The RCVS says the new Code is a short, principles-based document using the Federation of Veterinarians of Europe's Code of Conduct as the starting point. It will be supported by additional advice on specific areas of veterinary practice or issues, for example, clinical governance. It also includes:
Clare Tapsfield-Wright, Chairman of the Guides Review Working Party said: "Over the decade or so since it was last reviewed, not only has the Guide become unwieldy in places, but the way that regulators in general publish professional conduct rules has changed. Our draft new Code aims to clarify matters and bring us into line with best practice elsewhere.
"Animal owners are increasingly keen to understand the basis of what the veterinary profession considers to be good professional conduct. The new simplified Code should assist with this understanding."
The new Code, together with the consultation paper, can be downloaded at http://www.rcvs.org.uk/codeconsultation
Comments, which are welcomed from the profession and the public, should be sent by email to Christopher Murdoch, Secretary to the Guides Review Working Party, at c.murdoch@rcvs.org.uk by Friday, 24 June 2011.
A separate document is under development for veterinary nurses, which will share broadly similar underlying principles and will be the subject of its own consultation.
The RCVS Registered Veterinary Nurse Disciplinary Committee has suspended a Northants-based registered veterinary nurse who admitted to acting dishonestly with her employer, a client and a pet database company by taking home a patient that was supposed to have been euthanised.
During the two-day hearing, the Committee heard how Sally-Ann Roberts, formerly of the Best Friends Veterinary Group in Thrapston, had deliberately gone against the wishes of the owners of a 14-year-old Maine Coon cat called Jason that he be euthanised, rather than treated further, and instead had taken the cat home with her for "intensive nursing". Jason had subsequently escaped from Ms Robert's residence, leading her to fabricate a story, first to the pet database company, and then to Jason's owners and her employer, that he had escaped from the practice, before being returned by a member of the public two days later and then euthanised as originally requested.
Ms Roberts acted with her veterinary surgeon colleague Przemyslaw Bogdanowicz, who chose not to euthanise Jason and who, for his part, received a three-month suspension from the RCVS Disciplinary Committee in December 2012. She repeated the false account on a number of occasions, both orally and in written statements, and also forged the signature of Jason's owner on official documentation in order to substantiate her story.
Only when Ms Roberts was interviewed for a second time by her then employer's area manager, did she finally admit to what had actually happened. Shortly afterwards, Ms Roberts was suspended from the practice and, following an internal disciplinary hearing a few days later, was dismissed by them for gross misconduct, along with Mr Bogdanowicz. There was no evidence available as to what ultimately happened to Jason.
Explaining her actions to the Committee, Ms Roberts said she was upset that Jason's owners wanted him to be euthanised and felt that he could recover if given some love and attention. She had asked Mr Bogdanowicz to discuss this possibility with Jason's owners, but he had refused, agreeing instead that she could continue Jason's treatment at her home. After Jason escaped, Ms Roberts said she was "devastated" and had "panicked", inventing the story of Jason's escape to cover her actions, which she now acknowledged were "wrong" and "stupid", and which she "bitterly regretted". Ms Roberts expressed sorrow and remorse for her behaviour, which she said would never occur again, and stated that being a veterinary nurse was everything to her.
In view of the admitted facts, the Committee judged that Ms Robert's dishonesty and breach of client trust, as well the distinct risk of injury to which she exposed Jason, amounted to serious professional misconduct. In deciding on an appropriate sanction, the Committee balanced a number of aggravating factors (in particular, the forged signature) against Ms Roberts' "strong mitigation", which included her admitting the entirety of the charges against her, her medical and personal problems at the time, the insight she had shown into the effects of her actions on Jason's owners and her previous unblemished career.
Professor Peter Lees, chairing and speak on behalf of the Committee, said: "The Committee has concluded that the Respondent has shown insight into the seriousness of her misconduct and that there is no significant risk of repeat behaviour. In light of the Respondent's admission, her insight, her remorse and the high regard in which she is held by her professional colleagues, it is the Committee's view that the sanction of two months' suspension is appropriate and proportionate."
The Committee's full decisions on facts and sanction are available at www.rcvs.org.uk/disciplinary.
Developed by Italian tech company, Otech Industry srl, the Onemytis 2 uniquely uses gas ionisation to vaporise tissue at lower temperatures and, claims Excel, with greater precision than is possible with conventional electrosurgery.
The knife works by a strong electromagnetic field through air. This releases plasma which vaporises tissue at a maximum operating temperature of 50°C (compared to more than 118°C in conventional electrosurgery).
During surgery, the electrode does not touch the patient. Plasma is formed when it is between 1 and 2 mm away from the patient, depending on the power setting. This means the surgeon does not apply any pressure when creating an incision, allowing greater precision.
The Onemytis range starts from £4500 +VAT.
West Sussex first opinion vet, Julian Hoad, Head of Crossways Veterinary Group, started using Onemytis last year for a range or procedures including laparoscopic surgery and the removal of masses, often without the need for a general anaesthetic.
Julian said: "I’ve used electrosurgery for 20 years and this is an order of magnitude better. It is more precise, more reliable and results in a much better healing surface."
"I recently removed an enlarged lymph node. The mass was around the mesenteric root. Because Onemytis is so precise I was able to dissect around the blood vessels, removing tissue that was attached to them with no blood loss. Onemytis is also excellent for removing epulides. It cuts though gingival tissue with very limited burning and produces very good, pain-free healing."
"I now routinely use it for performing nostril widening surgery in brachycephalic dogs; it reduces surgery time dramatically and completely abolishes bleeding in most cases."
"I have also used it to remove a large mass from a dog’s spleen and, by using a combination of Onemytis and Ligasure, managed to do so with a total blood loss of less than 2 ml."
Steve Hayden, Director at Excel Lasers, said: “We are delighted to be bringing Onemytis 2 to the UK. An important part of our role is to identify the technological innovations we think are most likely to help vets and their patients and Onemytis really stands out. The feedback we have had from our clients has been extremely positive and we think it has a fantastic future in veterinary surgery.”
To find out more about Onemytis 2 and watch videos of it in action, visit: https://www.excellasers.com/airplasma/
The charity says that one of the biggest issues it faces with guinea pigs is multi-animal households where breeding has become out of control.
Dr Jane Tyson, the RSPCA’s rodent expert, said: "We would always advise owners to have their male guinea pigs neutered before introducing them to a female. We also find that they can sometimes be mis-sexed by the seller or previous owner which leads to accidental breeding so it’s also important to make sure that guinea pigs see a vet regularly who would be able to spot if they have been identified incorrectly.
“Many of the guinea pigs that come into our care have come from a multi-animal home where there have been large numbers of guinea pigs living in often cramped, dirty and unsuitable conditions. This also means that they may have experienced very little handling and are wary and fearful of human hands and need their confidence building up in RSPCA care.
“This is why, this Guinea Pig Appreciation Day, we wanted to encourage people to neuter their guinea pigs and help tackle the problem of overbreeding.”
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
References
The company says that the packs have been redesigned to make it easier for pet owners to identify the variety of products available.
The new packaging has stronger imagery, simplified and larger product names to improve readability, and kibble shapes displayed actual size to reassure owners of smaller breeds that it will be suitable for their pet. Flavour profiles and breed sizes are displayed on all packs.
Hill's says the new range is also presented in optimised bag sizes for more convenient feeding. Small and Miniature and Mini dog foods have been combined into a new Small & Mini product, designed to cover the needs of all small dogs under 10kg.
For more information, visit: https://www.hillspet.co.uk/science-plan/new-look.
The charity says that it had already been suffering a period of 'dire financial constraints' and the economic effects of coronavirus are now having a direct effect on funding.
The charity's Trustees and Executive Committee is still trying to find emergency funding to try and save the organisation, failing which it will close on the 31st March.
Sporimune is the first ciclosporin oral solution to be licensed for use in both cats and dogs.
In cats with allergic dermatitis, ciclosporin has proved to be an effective alternative to prednisolone1 Dechra says it has a long-term safety record for chronic treatment of canine atopic dermatitis and remains one of the most important tools within a multi-modal strategy.
Sporimune is available with two dosing syringes per bottle – one for cats and one for dogs – that are graduated in body weight and ml.
There are three bottle sizes to allow for flexibility in dispensing and broached bottles last six months.
Dechra Brand Manager Claire Morgan said: "We are delighted to be able to introduce this popular and effective treatment for cats.
"Allergic skin disease can be challenging to diagnose and manage effectively for both owners and vets, with around 20 per cent of all small animal consultations involving skin conditions.
"Sporimune is a key component of a multi-modal approach involving guidance on allergen and flare factor avoidance and improving skin and coat hygiene to minimise clinical signs and the effects on quality of life for both animal and owner."
A survey carried out by Rachel Crowe BSc PhD in association with Virbac Animal Health and VetSurgeon.org has revealed what veterinary surgeons in the UK expect from pharmaceutical companies and other suppliers.
The survey considers a number of different aspects of the relationship between vets and pharmaceutical companies, from the importance of quality products through to the question of what vets expect from company representatives.
Chris Liggett, Marketing Director at Virbac UK said: "The findings of this survey offer a fascinating insight into the relationship between veterinary practices and their suppliers. In some ways they confirm what we should all already know - that the quality of a company's product range is paramount and that representatives play a key role as ambassadors for our businesses - but the growing importance to vet practices of working with drug companies that provide a complete package of products and services is worthy of note."
The full report is available to download here.
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
The BSAVA has announced the launch of its third smartphone app - the BSAVA Small Animal Formulary App.
This member-only access app is available to download now from iTunes and Android Market and offers the same reference materials found in the latest 7th edition printed version.
The BSAVA says the app contains more than 450 drug monographs and a wealth of additional information, allowing easy and rapid access to vital information about those medications that veterinary surgeons most commonly prescribe. It is hoped that the convenience of having the BSAVA Small Animal Formulary on a smartphone will mean that vets in practice will always have this valuable reference tool within easy reach.
Once the app is installed it will ask for a validation code that can be obtained from the smartphone app validation code page within My BSAVA pages at www.bsava.com. All future BSAVA member-only smartphone apps will be validated using the same process.
BSAVA IT Manager Emma Hayes said: "BSAVA is continually aiming to provide a range of valuable member benefits in a variety of formats so they can be used in the most efficient and effective way by our members. The BSAVA Formulary was a natural candidate for release as a mobile application, following the successful launch as an online searchable database at Congress in April. By developing this application it has also provided us with a platform that will enable us to produce additional useful applications in the future that can provide unrestricted content for our members."
The BSAVA Small Animal Formulary App follows on from the BSAVA Congress App and the BSAVA Guide to the use of Veterinary Medicines App. You can find out more about these other BSAVA smartphone apps through My BSAVA at www.bsava.com.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
Northwest Surgeons, the Cheshire-based referral centre which is now part of Pets at Home, has announced the expansion of its clinical specialisms into the field of neurology, with the appointment of Dr Lorenzo Golini.
Dr Golini underwent residency training in neurology and neurosurgery at the University of Zurich where he remained as a clinician after his residency. He holds the European Diploma in Veterinary Neurology and a Master's degree in behavioural medicine. His main interests lie in epilepsy and MRI.
Dr Chris May, Northwest Surgeons' Managing Director said: "Neurology is a natural extension of the services we offer currently and is an area of growth in response to an increased demand from our referring vets. I am delighted to welcome Lorenzo to our team."
Dr Golini will accept referrals for both medical and surgical neurology cases, expanding on the case load seen by Northwest Surgeons' existing specialist teams which offer referrals in orthopaedic, soft tissue and spinal surgery and internal medicine. These services are supported by veterinary specialists in anaesthesia, pain management and diagnostic imaging.
For more information, visit: www.nwsurgeons.co.uk
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."